SELETRACETAM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H14F2N2O2
Molecular Weight	232.2272
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=O

InChI

InChIKey=ANWPENAPCIFDSZ-RQJHMYQMSA-N

InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H14F2N2O2
Molecular Weight	232.2272
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19055493 | https://www.ncbi.nlm.nih.gov/pubmed/17199025 | https://www.ncbi.nlm.nih.gov/pubmed/18183537

Seletracetam, a pyrrolidone derivative is a new drug in epilepsy development. Seletracetam has high binding affinity to the synaptic vesicle 2A (SV2A) protein. In addition, was discovered, that the drug bound to N-type calcium channels and inhibited high-voltage-activated Ca2+ currents and intracellular Ca2+ increase. Seletracetam participated in Phase III clinical trials; however, all these studies for the treatment of epilepsy were terminated. Moreover, it is unknown whether planned phase IIb/III trials will begin.

Originator

Approval Year

PubMed

Title	Date	PubMed
Antiepileptic drug discovery: lessons from the past and future challenges.	2005	16238713
Drugs in development for Parkinson's disease: an update.	2006 Jan	16425668
New antiepileptic drugs that are second generation to existing antiepileptic drugs.	2006 Jun	16732716
Diverse mechanisms of antiepileptic drugs in the development pipeline.	2006 Jun	16621450
Seletracetam (UCB 44212).	2007 Jan	17199025
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).	2007 Jan	17158031
The effectiveness of anticonvulsants in psychiatric disorders.	2008	18472486
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster.	2008 Dec 28	19014930
Modifications of antiepileptic drugs for improved tolerability and efficacy.	2008 Feb 14	19787095
Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.	2008 Jan	18183537
Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro.	2009 Apr	19055493
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.	2009 Jul 1	19383493
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.	2009 Mar-Apr	19443931
Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression.	2010 Feb 1	20039359
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.	2010 Feb 12	20166767

Patents

Sample Use Guides

In Vivo Use Guide

Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years)

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:30:35 UTC 2023` Edited by `admin` on `Fri Dec 15 15:30:35 UTC 2023`
Record UNII	RFR2CH3QZK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SELETRACETAM

Official Name

English

seletracetam [INN]

Common Name

English

SELETRACETAM [USAN]

Common Name

English

UCB-44212

Code

English

UCB 44212

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C264